| In millions, except per share items | Mar-31-14 | Mar-31-13 | Mar-31-12 | Mar-31-11 | Mar-31-10 | Mar-31-09 | Mar-31-08 | Mar-31-07 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| United States | 175.3 | 133.0 | 109.1 | 98.1 | 70.3 | 89.6 | 107.7 | 106.5 |
| China | 80.0 | 79.5 | 74.9 | 65.8 | 51.3 | 41.7 | 55.9 | 45.6 |
| France | 74.8 | 62.6 | 55.9 | 45.9 | 36.2 | 28.1 | 28.0 | 21.6 |
| Ireland | 29.7 | 28.2 | 28.6 | 31.1 | 20.8 | 12.0 | 13.0 | 11.0 |
| Other | 52.9 | 43.7 | 44.7 | 33.9 | 26.4 | 28.4 | 23.7 | 15.6 |
| Total revenues | 412.7 | 347.0 | 313.2 | 274.8 | 205.0 | 199.9 | 228.4 | 200.3 |
| Revenue growth [+] | 18.9% | 10.8% | 14.0% | 34.0% | 2.6% | -12.5% | 14.0% | 64.9% |
| United States | 31.8% | 22.0% | 11.2% | 39.6% | -21.5% | -16.9% | 1.2% | 55.0% |
| China | 0.7% | 6.1% | 13.9% | 28.2% | 23.1% | -25.5% | 22.7% | 48.6% |
| France | 19.5% | 12.0% | 21.8% | 26.9% | 28.7% | 0.3% | 29.9% | 24.1% |
| Ireland | 5.4% | -1.6% | -7.9% | 49.3% | 72.9% | -7.2% | 17.9% | |
| Switzerland | 43.1% | -7.8% | 15.9% | 41.6% | -14.3% | 197.3% | | |
| Cost of goods sold | 240.7 | 204.9 | 187.3 | 160.0 | 126.4 | 116.6 | 133.0 | 112.8 |
| Gross profit | 171.9 | 142.1 | 125.9 | 114.8 | 78.6 | 83.2 | 95.4 | 87.4 |
| Gross margin | 41.7% | 41.0% | 40.2% | 41.8% | 38.4% | 41.6% | 41.8% | 43.7% |
| Selling, general and administrative | 121.9 | 101.5 | 90.0 | 78.7 | 69.9 | 71.1 | 67.5 | 65.0 |
| Research and development | | | | | | | | |
| Equity in earnings | 0.7 | 0.7 | 0.8 | 0.6 | 0.4 | 0.4 | | |
| Other operating expenses | | -0.5 | -0.4 | | | | | |
| EBITDA [+] | 71.1 | 59.6 | 53.9 | 51.6 | 23.2 | 25.7 | 37.8 | 32.1 |
| EBITDA growth | 19.4% | 10.6% | 4.4% | 122.5% | -9.9% | -31.9% | 17.6% | 50.9% |
| EBITDA margin | 17.2% | 17.2% | 17.2% | 18.8% | 11.3% | 12.9% | 16.5% | 16.1% |
| Depreciation | 11.1 | 9.8 | 9.1 | 14.9 | 14.1 | 13.2 | 9.9 | 9.7 |
| EBITA | 60.0 | 49.8 | 44.8 | 36.7 | 9.1 | 12.5 | 27.9 | 22.5 |
| EBITA margin | 14.5% | 14.3% | 14.3% | 13.4% | 4.4% | 6.3% | 12.2% | 11.2% |
| Amortization of intangibles | 9.3 | 8.1 | 7.7 | | | | | |
| EBIT [+] | 50.7 | 41.7 | 37.1 | 36.7 | 9.1 | 12.5 | 27.9 | 22.5 |
| EBIT growth | 21.6% | 12.3% | 1.1% | 302.7% | -27.2% | -55.1% | 24.1% | 42.4% |
| EBIT margin | 12.3% | 12.0% | 11.9% | 13.4% | 4.4% | 6.3% | 12.2% | 11.2% |
| Non-recurring items [+] | | 0.5 | 0.4 | | | | | |
| Asset impairment | | 0.5 | 0.4 | | | | | |
| Interest expense | 3.2 | 2.7 | 2.6 | 3.0 | 3.9 | 3.1 | 4.5 | 6.1 |
| Interest expense | 3.2 | 2.7 | 2.6 | 3.0 | 3.9 | 3.1 | 4.5 | 6.1 |
| Other income (expense), net [+] | 0.5 | 4.0 | -0.3 | -0.6 | 0.9 | -0.5 | -0.5 | -0.8 |
| Gain (loss) on foreign currency transactions | 1.1 | -0.1 | -0.2 | 0.4 | -1.0 | | | |
| Other | -0.5 | 0.0 | 0.1 | -0.2 | 0.1 | | | |
| Pre-tax income | 48.0 | 42.5 | 33.9 | 33.0 | 6.1 | 8.9 | 22.8 | 15.6 |
| Income taxes | 10.3 | 8.3 | 6.2 | 4.8 | 0.1 | 3.6 | 6.0 | 3.1 |
| Tax rate | 21.4% | 19.6% | 18.2% | 14.7% | 0.9% | 40.8% | 26.3% | 20.0% |
| Minority interest | | | | | | | 0.4 | 0.5 |
| Earnings from continuing ops | 37.8 | 34.2 | 27.7 | 28.2 | 6.1 | 5.3 | 16.8 | 14.2 |
| Earnings from discontinued ops | | | | | | | | 2.3 |
| Net income | 37.8 | 34.2 | 27.7 | 28.2 | 5.9 | 5.3 | 16.8 | 14.2 |
| Net margin | 9.1% | 9.9% | 8.8% | 10.3% | 2.9% | 2.6% | 7.4% | 7.1% |
| |
| Basic EPS [+] | $2.39 | $2.22 | $1.84 | $1.92 | $0.42 | $364.95 | $1.17 | $1.01 |
| Growth | 7.5% | 21.1% | -4.2% | 358.9% | -99.9% | 31083.4% | 16.4% | -43.8% |
| Diluted EPS [+] | $2.26 | $2.12 | $1.74 | $1.84 | $0.41 | $362.20 | $1.16 | $0.99 |
| Growth | 6.9% | 21.7% | -5.4% | 345.4% | -99.9% | 31171.3% | 17.4% | -42.3% |
| |
| Shares outstanding (basic) [+] | 15.8 | 15.4 | 15.1 | 14.7 | 14.5 | 0.0 | 14.4 | 14.2 |
| Growth | 2.7% | 2.0% | 2.7% | 1.3% | 100128.1% | -99.9% | 1.4% | 3.3% |
| Shares outstanding (diluted) [+] | 16.7 | 16.2 | 15.9 | 15.3 | 14.7 | 0.0 | 14.5 | 14.4 |
| Growth | 3.3% | 1.4% | 3.9% | 4.4% | 100661.6% | -99.9% | 0.6% | 0.5% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |